ArticleArquivos de neuro-psiquiatria2026
Effect of nerolidol on seizure and oxidative brain damage induced by pentylenetetrazole in mice.
Article in Arquivos de neuro-psiquiatria, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Nerolidol, a natural sesquiterpene alcohol found in essential oils, has demonstrated antioxidant, anti-inflammatory, and neuroprotective properties. However, its effects on pentylenetetrazole (PTZ)-induced seizure and associated oxidative brain damage remain unclear. Objective: To evaluate the anticonvulsant effects of nerolidol on PTZ-induced seizures in mice and to investigate its impact on oxidative and nitrosative stress markers in the hippocampus and cortex. Methods: Male mice were divided into 5 groups: control, PTZ, and PTZ pretreated with nerolidol (25, 50, or 100 mg/kg, orally) 30 minutes before PTZ administration. Seizure activity was assessed by measuring latencies to minimal clonic seizures (MCSs) and generalized tonic-clonic seizures (GTCSs). After a behavioral evaluation, hippocampal and cortical tissues were analyzed for malondialdehyde (MDA), nitric oxide (NO) metabolites, superoxide dismutase (SOD), catalase (CT), and total thiol content. Results: Nerolidol significantly increased MCS and GTCS latencies compared with the PTZ group. In the hippocampus, all doses reduced MDA levels, while in the cortex this effect was observed at 50 and 100 mg/kg. Nitric oxide metabolites were decreased by the two higher doses in both brain regions. The PTZ-induced reductions in SOD and CT activities were reversed by nerolidol at all doses, and total thiol levels were restored at 50 and 100 mg/kg. Conclusion: Nerolidol exhibits anticonvulsant and neuroprotective effects on PTZ-induced seizures, likely mediated by reduced oxidative and nitrosative stress and enhancement of endogenous antioxidant defenses.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.